We read with great interest the correspondence by Momot et al. [1], which offers a thoughtful and constructive commentary on our recent narrative review exploring the role of epicardial fat assessment in clinical practice [2]. Their insights skilfully highlight the essential technical and clinical "bridges" that must be crossed to transform epicardial adipose tissue (EAT) from a promising pathophysiological concept into a robust, validated clinical tool. We welcome this opportunity to further elaborate our perspective on three critical areas: measurement standardization, incremental predictive value, and the evolving role of EAT as a risk factor and therapeutic target.
